Description from Figshare: "Table S5. Nonsynonymous single nucleotide variants (SNVs) and insertions/deletions (indels) identified by whole exome sequencing (WES) and/or initial panel sequencing. Each sheet is a different tumor sample."

Description from Figshare: "Table S1. Massively Parallel Sequencing (MPS) metrics and cancer sample characteristics."

Description from Figshare: "Table S2. Demographic and clinical characteristics of 30 cancer patients with mTOR pathway mutations. S2.1. Master table showing a summary of demographic characteristics and clinical outcomes. S2.2. Prior systemic treatment regimens. S2.3. Objective response to everolimus according to RECIST v1.1 criteria. S2.4. Toxicity profile of patients according to CTCAE v4.0."

Description from Figshare: "Table S3. Toxicities (any level) occurring in at least two patients, grouped by CTCAE v4.0 categories. For patients with more than one adverse event per category, only the highest-grade event was counted."

Description from Figshare: "Table S6. Copy number alterations (CNAs) in cancer genes identified by whole exome sequencing (WES) and/or initial panel sequencing. Each sheet is a different tumor sample."

Description from Figshare; "Table S4. Inactivating mutations in TSC1/TSC2 and activating mutation in MTOR identified in 30 patients in the clinical trial - clonality and biallelic TSC1/TSC2 inactivation status."

Description from Zenodo: "This is a de-identified dataset accompanying the Nature Medicine publication titled "Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial", by Vos et al. (DOI: https://doi.org/10.1038/s41591-023-02518-x). It contains the clinical features and processed data of 64 patients with salivary gland cancer, treated with nivolumab and ipilimumab immunotherapy....

Description from BioProject: "Salivary gland cancers (SGCs) are rare, aggressive cancers that lack effective treatments in the metastatic setting. We report the clinical results and immunogenomic correlates of response from a phase II trial evaluating nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) in metastatic SGC patients."